CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

NCT05291156 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

173

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Cetuximab
DRUG: Avelumab

Sponsor

University of Campania Luigi Vanvitelli